J1010 CPT Code Explained: Documentation Requirements and Billing Tips

This guide breaks it all down, piece by piece, in plain language. And if you are dealing with broader billing complexity across your practice, you will find that the same documentation discipline that protects J1010 claims also protects your entire revenue cycle a point we revisit throughout.

What Exactly Is the J1010 CPT Code? (Description)

Before diving into billing mechanics, it is worth grounding yourself in what this code actually represents.

J1010 is a HCPCS Level II code (technically classified under the J-code series, not traditional CPT, though billers routinely refer to it informally as the “J1010 CPT code”) used to report the administration of calfactant, an intratracheal suspension used as a pulmonary surfactant. Specifically, the J1010 CPT code description covers calfactant, 10 mg when administered intratracheally.

Calfactant sold under the brand name Infasurf is primarily used in neonatal care for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants. Because RDS develops when the newborn lung lacks adequate surfactant to maintain alveolar stability, this drug fills a critical therapeutic gap in neonatal intensive care units across the country.

Key code facts at a glance:

Detail	Value
Code	J1010
Drug Name	Calfactant (Infasurf)
Dosage Unit	Per 10 mg
Route	Intratracheal suspension
Setting	Hospital/neonatal intensive care
Code Type	HCPCS Level II

Because dosage is billed per 10 mg, the number of units you report must reflect the total milligrams administered divided by 10. Get that calculation wrong and you are either under-billing or worse triggering a post-payment audit. If your billing team also handles complex drug codes across multiple specialties, our medical coding services team can provide the kind of cross-specialty oversight that catches these errors systematically.

J1010 vs. J1030 Understanding the Difference

One of the most common sources of confusion in surfactant billing is the relationship between J1010 and the J1030 CPT code. Practices that care for premature infants will often encounter both codes, and mixing them up can mean denied claims and compliance headaches.

J1030 covers beractant (Survanta), another pulmonary surfactant used for neonatal RDS but a chemically and biologically distinct product from calfactant. Both codes belong to the same therapeutic category, but they are never interchangeable on a claim.

Here is the side-by-side breakdown:

Code	Drug	Brand	Unit Billed Per
J1010	Calfactant	Infasurf	10 mg
J1030	Beractant	Survanta	4 mg

The critical takeaway: the specific drug administered must drive your code selection every single time. Payers audit drug claims against pharmacy records, NDC numbers, and manufacturer invoice data. If your J1010 claim maps to a beractant NDC, the claim will fail.

For practices also managing coding across complex specialties, we have covered related topics like colonoscopy CPT codes and screening versus diagnostic billing the same payer-scrutiny logic applies. Code specificity is not a technicality; it is the foundation of a clean claim.

J1010 CPT Code NDC Requirements: Why NDC Reporting Is Not Optional

Here is something many billers overlook: for drug codes like J1010, NDC (National Drug Code) reporting is not just a payer preference it is frequently a mandatory claim element for Medicaid programs and a growing number of commercial payers.

The NDC number uniquely identifies the manufacturer, product, and package size of the drug. When you report J1010, payers use the NDC to cross-reference:

• Whether the drug matches the HCPCS code
• The invoice price for reimbursement calculations
• Manufacturer rebate tracking (especially important for Medicaid)

How to report the J1010 CPT code NDC correctly:

• On a CMS-1500 claim form or 837P electronic transaction, NDC data is typically entered in the shaded area of Box 24 with a specific qualifier
• Qualifier: N4 (indicates NDC number)
• Format: 11-digit NDC in 5-4-2 format (e.g., 55326-0101-01)
• Unit of measure: ML (milliliter) or UN (unit), depending on payer guidance
• Quantity: Actual quantity dispensed that corresponds to the NDC package

Infasurf (calfactant) has several NDC configurations depending on vial size. Always pull the NDC from the actual vial used not from a formulary list or database to ensure accuracy.

Missing or incorrect NDC data is one of the top five reasons drug claims are denied or flagged for post-payment review. If your practice is struggling with this type of rejection, our specialized rejected claims service helps practices systematically resolve and prevent these issues before they compound into revenue losses.

J1010 CPT Code Modifier Usage When and Why Modifiers Matter

The J1010 CPT code modifier conversation is one that can get surprisingly nuanced depending on payer, setting, and clinical scenario. The right modifier protects your claim; the wrong one or a missing one can sink it. Let’s walk through the most relevant modifier situations.

Modifier JW – Drug Wasted

If a portion of the calfactant vial was opened, used partially, and the remainder discarded (because the drug cannot be stored once opened), Modifier JW allows you to bill for the wasted portion. Many payers, including Medicare, have specific policies on JW usage the wasted amount must be documented in the medical record with a notation of the discard. Without JW, you can only bill for what was actually administered. With proper documentation and JW, you may recover the cost of the unused portion.

Modifier JZ – Zero Drug Waste

Introduced by CMS in 2023, Modifier JZ is the counterpart to JW. When the entire vial is used and there is no waste, JZ must be appended to confirm that fact. This modifier reduces audit scrutiny by explicitly affirming complete utilization. Post-2023, one of these two modifiers must appear on every separately payable drug claim no exceptions.

Modifier KD – Drug or Biological Infused Through DME

If the administration occurred through durable medical equipment in certain payer contexts, Modifier KD may be applicable.

Modifier 59 – Distinct Procedural Service

When J1010 is billed alongside other procedures on the same date of service, Modifier 59 may be needed to clarify that the drug administration is a separate, distinct service particularly when bundling edits would otherwise collapse the claim.

Modifier management across same-day codes is a nuanced discipline. For context on how this plays out in other specialties, our blog post on CPT 97110 billing and documentation covers modifier usage patterns that translate well across drug and procedure billing.

Documentation Requirements for J1010 Billing

If there is one area where claims collapse unnecessarily, it is documentation. Payers are increasingly conducting pre- and post-payment audits on high-cost drug codes, and J1010 given its use in neonatal ICU settings falls under heightened scrutiny.

Here is what must be present in the medical record to support a J1010 claim:

1. Physician Order a dated, signed order specifying calfactant (Infasurf), the dose in milligrams, route (intratracheal), and the clinical indication (RDS diagnosis).

2. Administration Record The nursing or respiratory therapy record must document:

• Date and time of administration
• Actual dose given (in mg)
• Lot number and NDC of the vial used
• Name of the administering provider
• Any waste and the reason for it

3. Diagnosis Linkage the ICD-10 diagnosis code must logically support the use of calfactant. For neonatal RDS, the primary supporting code is P22.0 (Respiratory distress syndrome of newborn). The diagnosis must appear on the claim and must be consistent with what is documented in the chart. Mismatched diagnosis-to-drug linkages are among the leading reasons for medical necessity denials a problem we explored in detail in our CPT and ICD-10 billing guide for colonoscopy, and the principle carries directly into drug code billing.

4. Drug Cost Documentation for Medicaid and many commercial payers, invoice-level acquisition cost documentation can be required during audits. Keeping pharmacy purchase records organized and accessible is not just good practice it can be the difference between keeping and returning a reimbursement.

5. Medical Necessity the record must reflect clinical indicators that support the use of a surfactant, including gestational age, birth weight, clinical findings consistent with RDS, and response to treatment.

Practices using electronic health records with structured documentation templates can build a J1010-specific documentation checklist into their EHR workflow, dramatically reducing audit risk and ensuring nothing gets missed at the point of care.

J1010 Administration Code Pairing the Drug with the Right Procedure Code

Here is a billing nuance that trips up even experienced coders: the drug code (J1010) and the administration code are two separate billable elements.

J1010 covers the drug itself. The act of administering it the clinical service is billed separately using the appropriate administration code. In a hospital outpatient or physician office setting, this typically involves codes from the 96365–96379 series (therapeutic injections and infusions) or applicable respiratory care codes depending on how the intratracheal administration is classified by your payer.

For neonatal settings, the administration of intratracheal surfactant may also be captured under specific critical care or procedure codes depending on the clinical context and facility type.

Why this matters: Billing only J1010 without the administration code leaves reimbursement on the table. Billing the administration code without J1010 means the drug cost goes unrecovered. Both must appear together, properly linked, for the claim to be whole.

This is one of the highest-yield areas our medical billing services team addresses during claims scrubbing. If your practice has been submitting drug claims without consistently pairing administration codes, a billing audit can reveal significant uncaptured revenue.

J1010 CPT Code Reimbursement: What to Expect

Let’s talk numbers because at the end of the day, reimbursement accuracy is the whole point.

Medicare: CMS assigns an ASP (Average Sales Price) based reimbursement rate for most separately payable drugs under Part B. For J1010, the Medicare rate is typically set at ASP + 6% for physician office or outpatient settings. Rates are updated quarterly, so you should check the current CMS drug pricing file not assume last quarter’s rate still applies.

Medicaid: Each state Medicaid program sets its own rate, which may be based on Wholesale Acquisition Cost (WAC), Federal Upper Limit (FUL), or a state-specific formula. NDC reporting is almost always mandatory for Medicaid drug claims, and rebate clawbacks can affect net reimbursement after the fact.

Commercial Payers: Contracted rates vary widely. Some use ASP-based logic; others apply a percentage of AWP (Average Wholesale Price). Review your payer contracts carefully the J1010 CPT code price under a poorly negotiated contract can result in reimbursement below your actual acquisition cost.

Acquisition vs. Reimbursement Gap: Calfactant is not an inexpensive drug. When the spread between what you pay for the vial and what the payer reimburses is thin or negative — it signals a contract renegotiation conversation. Practices supported by robust analytics and reporting tools can track this spread systematically and build the case for better rates with data that payers cannot argue away.

Common Billing Mistakes with J1010 And How to Avoid Them

These are the mistakes that actually show up in billing audits, not just theoretical errors:

Mistake 1: Wrong Units Billing 1 unit when 3 units (30 mg) were administered. Units must reflect total mg administered ÷ 10. This is one of the most frequent calculation errors on drug claims across all HCPCS codes.

Mistake 2: Missing NDC Submitting J1010 to Medicaid without the NDC qualifier, number, and quantity will result in a denial every time. There are no exceptions on most state Medicaid platforms.

Mistake 3: Forgetting JW or JZ Post-2023, CMS requires one of these modifiers on every separately payable drug claim. Missing both is a compliance red flag and will increasingly trigger automated rejections.

Mistake 4: No Diagnosis Link A J1010 claim with no supporting RDS or related neonatal diagnosis will fail medical necessity review. The ICD-10 must be on the claim, must match the chart, and must logically connect to calfactant as the appropriate therapeutic response. For a broader look at how diagnosis linkage errors drive denials, see our piece on abnormal EKG ICD-10 coding the principle of matching clinical documentation to diagnosis codes applies universally.

Mistake 5: Billing Drug Without Administration Code This is lost revenue, pure and simple. The administration service must be coded separately.

Mistake 6: Using J1030 When J1010 Was the Administered Drug These are different drugs. Never swap codes. Payer systems cross-reference NDC numbers and will flag mismatches.

For practices that want a systematic approach to catching these errors before claims go out the door, working with a professional billing partner that conducts pre-submission claims scrubbing as part of their quality billing services is the most reliable solution.

J1010 Billing Guidelines: Pre-Submission Checklist

• Confirm drug administered is calfactant (Infasurf), not beractant or another surfactant
• Calculate units correctly: total mg administered ÷ 10
• Attach the correct NDC in 5-4-2 format with N4 qualifier and unit of measure
• Append JW (if waste occurred and is documented) or JZ (if full vial used)
• Include the separate administration code
• Link to a supporting ICD-10 diagnosis code (P22.0 for neonatal RDS)
• Confirm payer-specific NDC reporting requirements
• Verify current reimbursement rate via CMS ASP file or payer contract
• Document physician order, administration record, and lot number in chart
• Confirm acquisition cost documentation is on file for audit readiness

How This Connects to Broader Revenue Cycle Health

J1010 billing is narrow in scope one drug, one neonatal indication but the discipline it demands mirrors what every strong revenue cycle requires: code specificity, documentation completeness, modifier accuracy, and payer-aware claim construction.

Practices that build these habits around one high-scrutiny code like J1010 often find the same rigor improves results across their entire billing portfolio. Whether it is managing chronic anticoagulation ICD-10 coding or navigating orthostatic hypotension coding for cardiology claims, the underlying principle is identical — the closer your claim reflects what actually happened clinically, the fewer denials you face.

For practices that handle pediatric billing services or neonatal ICU work alongside adult specialties, that integrated discipline becomes a competitive advantage in payer negotiations and audit defense alike.

When to Bring in a Professional Billing Partner

There is no shame in acknowledging that neonatal drug billing especially for high-cost, high-scrutiny codes like J1010 requires a level of specialized expertise that not every in-house billing team has fully developed. The stakes are real: under-billing leaves money uncollected, while over-billing (even accidentally) creates compliance exposure that can cost far more to resolve than it would have cost to get right in the first place.

At A2Z Billings, we work with practices across a wide range of specialties from pharmacy billing services to laboratory billing services to complex neonatal and pediatric care to ensure that drug codes like J1010 are submitted correctly, completely, and in a way that holds up to payer scrutiny.

Our team understands the specific billing guidelines that govern HCPCS drug codes, including NDC reporting obligations, modifier mandates, and ASP-based reimbursement mechanics. We also stay current as payer policies shift — because in this field, what was correct last year may not be compliant this year.

If your practice is seeing a pattern of J1010 denials, underpayments, or audit notices, that is a signal worth taking seriously. Contact our team for a billing review and let us identify where revenue is leaking and how to close those gaps permanently.